DHR Stock - Danaher Corporation
Unlock GoAI Insights for DHR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $23.88B | $23.89B | $26.64B | $29.45B | $22.28B |
| Gross Profit | $14.21B | $14.03B | $16.19B | $17.95B | $12.47B |
| Gross Margin | 59.5% | 58.7% | 60.8% | 61.0% | 56.0% |
| Operating Income | $5.18B | $5.28B | $7.54B | $8.05B | $4.31B |
| Net Income | $3.90B | $4.76B | $7.21B | $6.43B | $3.65B |
| Net Margin | 16.3% | 19.9% | 27.1% | 21.8% | 16.4% |
| EPS | $5.33 | $6.44 | $9.80 | $8.77 | $4.97 |
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Goldman | Initiation | Buy | $265 |
| December 2nd 2025 | Morgan Stanley | Initiation | Overweight | $270 |
| October 8th 2025 | Rothschild & Co Redburn | Downgrade | Neutral | $220 |
| July 11th 2025 | Scotiabank | Upgrade | Sector Outperform | $275 |
| April 10th 2025 | Barclays | Upgrade | Overweight | $205 |
| March 21st 2025 | Goldman | Upgrade | Buy | $260 |
| March 14th 2025 | Stifel | Upgrade | Buy | $260 |
| February 3rd 2025 | Raymond James | Downgrade | Market Perform | - |
| December 23rd 2024 | Scotiabank | Initiation | Sector Perform | - |
| December 19th 2024 | Guggenheim | Initiation | Buy | $275 |
| December 13th 2024 | BofA Securities | Upgrade | Buy | $290 |
| October 31st 2024 | Wolfe Research | Upgrade | Outperform | $285 |
| October 1st 2024 | Stephens | Initiation | Overweight | $315 |
| August 28th 2024 | Wells Fargo | Initiation | Equal Weight | $280 |
| June 3rd 2024 | Jefferies | Resumed | Buy | $295 |
Earnings History & Surprises
DHREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 20, 2026 | — | — | — | — |
Q1 2026 | Jan 28, 2026 | $2.14 | — | — | — |
Q4 2025 | Oct 21, 2025 | $1.72 | $1.89 | +9.9% | ✓ BEAT |
Q3 2025 | Jul 22, 2025 | $1.64 | $1.80 | +9.8% | ✓ BEAT |
Q2 2025 | Apr 22, 2025 | $1.63 | $1.88 | +15.3% | ✓ BEAT |
Q1 2025 | Jan 29, 2025 | $2.14 | $2.14 | 0.0% | = MET |
Q4 2024 | Oct 22, 2024 | $1.57 | $1.71 | +8.9% | ✓ BEAT |
Q3 2024 | Jul 23, 2024 | $1.57 | $1.72 | +9.6% | ✓ BEAT |
Q2 2024 | Apr 23, 2024 | $1.72 | $1.92 | +11.6% | ✓ BEAT |
Q1 2024 | Jan 30, 2024 | $1.90 | $2.09 | +10.0% | ✓ BEAT |
Q4 2023 | Oct 24, 2023 | $1.83 | $2.02 | +10.4% | ✓ BEAT |
Q3 2023 | Jul 25, 2023 | $2.00 | $2.05 | +2.5% | ✓ BEAT |
Q2 2023 | Apr 25, 2023 | $2.25 | $2.36 | +4.9% | ✓ BEAT |
Q1 2023 | Jan 24, 2023 | $2.54 | $2.87 | +13.0% | ✓ BEAT |
Q4 2022 | Oct 20, 2022 | $2.26 | $2.56 | +13.3% | ✓ BEAT |
Q3 2022 | Jul 21, 2022 | $2.35 | $2.76 | +17.4% | ✓ BEAT |
Q2 2022 | Apr 21, 2022 | $2.66 | $2.76 | +3.8% | ✓ BEAT |
Q1 2022 | Jan 27, 2022 | $2.54 | $2.69 | +5.9% | ✓ BEAT |
Q4 2021 | Oct 21, 2021 | $2.14 | $2.39 | +11.7% | ✓ BEAT |
Q3 2021 | Jul 22, 2021 | $2.05 | $2.46 | +20.0% | ✓ BEAT |
Latest News
Wells Fargo Maintains Equal-Weight on Danaher, Raises Price Target to $240
➖ NeutralGoldman Sachs Initiates Coverage On Danaher with Buy Rating, Announces Price Target of $265
📈 PositiveMorgan Stanley Initiates Coverage On Danaher with Overweight Rating, Announces Price Target of $270
📈 PositiveWells Fargo Maintains Equal-Weight on Danaher, Raises Price Target to $230
📈 PositiveTD Cowen Maintains Buy on Danaher, Raises Price Target to $260
📈 PositiveBarclays Maintains Overweight on Danaher, Raises Price Target to $250
📈 PositiveDanaher rises as Diagnostics unit powers Q3 beat
📈 PositiveDanaher shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveDanaher Affirms FY2025 Adj EPS Guidance of $7.70-$7.80 vs $7.78 Est
📈 PositiveDanaher Q3 Adj. EPS $1.89 Beats $1.72 Estimate, Sales $6.053B Beat $6.007B Estimate
📈 PositiveRothschild & Co Downgrades Danaher to Neutral, Lowers Price Target to $220
📉 NegativeEvercore ISI Group Maintains Outperform on Danaher, Raises Price Target to $245
📈 PositiveB of A Securities Maintains Buy on Danaher, Lowers Price Target to $220
➖ NeutralFrequently Asked Questions about DHR
What is DHR's current stock price?
What is the analyst price target for DHR?
What sector is Danaher Corporation in?
What is DHR's market cap?
Does DHR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to DHR for comparison